查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602778

驅蟲藥市場：按藥物類別、給藥途徑、目標病原體、應用、分銷管道 - 全球預測 2025-2030

Anthelmintic Drugs Market by Drug Class (Benzimidazoles, Piperazine), Route of Administration (Injectable, Oral), Target Pathogen, Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年驅蟲藥市值為33億美元，預計2024年將達35.7億美元，複合年成長率為8.02%，預計2030年將達到56.8億美元。

驅蟲藥對於治療寄生蟲引起的感染疾病至關重要，在維護公共衛生和獸醫領域中發揮重要作用。這些藥物的使用範圍擴大到預防和治療血吸蟲病、絲蟲病和其他影響人類和動物的寄生蟲相關疾病。由於全球旅行的增加、不受管制地使用會滋生抗藥性細菌的市售驅蟲藥物以及人們對動物保健重要性的認知的提高，對這些藥物的需求進一步增加。主要用於農業和人類醫療保健設施，應用範圍從大規模驅蟲計劃到常規獸醫實踐。最終用戶包括醫院、診所、製藥公司和畜牧業。

主要市場統計
基準年[2023] 33億美元
預計年份 [2024] 35.7億美元
預測年份 [2030] 56.8億美元
複合年成長率（%） 8.02%

市場成長受到蠕蟲感染疾病增加、提高療效的藥物配方進步以及主要企業之間為擴大市場而建立的策略聯盟等因素的影響。最近的市場狀況有利於新興市場的創新給藥方法和配方，驅蟲正成為公共衛生政策的重要組成部分。擴大服務範圍並提高意識可以顯著提高市場滲透率。然而，挑戰依然存在，包括日益成長的抗藥性威脅、嚴格的監管政策以及限制新藥開發和採用的潛在副作用。

創新的時機尤其成熟，例如開發具有低抗藥性的頻譜驅蟲藥和針對特定地區寄生蟲的藥物。同樣重要的是要關注在不影響療效的情況下減少給藥頻率的研究。市場的性質要求在研究和監管方面投入大量資金，要求企業專注於策略夥伴關係和持續創新。透過投資加強分子研究和生物資訊學，公司可以預測抗藥性模式並提供解決方案來滿足新興需求。市場成功的關鍵在於平衡技術創新與嚴格遵守和預測市場需求。

市場動態：揭示快速發展的驅蟲藥市場的關鍵市場洞察

供需的動態交互作用正在改變驅蟲藥市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 隨著人們對維護動物健康的興趣日益濃厚，養寵物的數量也不斷增加。
    • 增加動物保健和健康支出
    • 蠕蟲感染疾病的加速流行
  • 市場限制因素
    • 抗寄生蟲藥物高成本
  • 市場機會
    • 增加動物保健服務中心
    • 驅蟲藥作為癌症免疫調節劑的出現
  • 市場挑戰
    • 對抗藥性的擔憂

波特五力：駕馭驅蟲藥市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解驅蟲藥市場的外部影響

外部宏觀環境因素在塑造驅蟲藥市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解驅蟲藥市場競爭狀況

對驅蟲藥市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣驅蟲藥市場供應商績效評估

FPNV定位矩陣是評估驅蟲藥市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了驅蟲藥市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，驅蟲藥市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 寵物擁有量的增加和對動物保護的興趣日益濃厚

健康

      • 增加動物保健和健康支出
      • 加速寄生蟲感染疾病的傳播
    • 抑制因素
      • 驅蟲藥高成本
    • 機會
      • 增加獸醫保健服務中心
      • 驅蟲藥作為癌症免疫調節劑的出現
    • 任務
      • 對產生抗藥性的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的驅蟲藥市場

  • 苯並咪唑酮
  • Piperazine

第7章驅蟲藥市場：依給藥途徑

  • 可注射的
  • 口服

第8章以目標病原體分類的驅蟲藥市場

  • 十二指腸鉤蟲
  • 蛔蟲
  • 蟯蟲
  • 鞭蟲

第9章驅蟲藥市場：依應用分類

  • 動物
  • 人類
    • 胃腸道感染疾病
    • 實質神經囊蟲病

第10章驅蟲藥市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 動物醫院/診所
  • 獸醫藥房

第11章美洲驅蟲藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太驅蟲藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲/中東/非洲驅蟲藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Aden Healthcare
  • Anikem Laboratories
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Cipla Limited
  • Dechra Pharmaceuticals PLC
  • Dr.Reddys Laboratories Inc.
  • Edenbridge Pharmaceuticals LLC
  • GlaxoSmithKline PLC
  • Green Cross Remedies
  • Healthy Life Pharma Private Limited
  • Johnson & Johnson Services, Inc.
  • Kosher Pharmaceuticals
  • Lineage Therapeutics Inc
  • Lupin Limited
  • Mankind Pharma Ltd.
  • McKesson Corporation
  • Merck & Co., Inc.
  • Norbrook Laboratories Limited
  • Novartis AG
  • Sankur Pharmaceuticals Pvt. Ltd
  • Takeda Pharmaceutical Company Limited
  • Virbac SA
Product Code: MRR-FB6C9E792F81

The Anthelmintic Drugs Market was valued at USD 3.30 billion in 2023, expected to reach USD 3.57 billion in 2024, and is projected to grow at a CAGR of 8.02%, to USD 5.68 billion by 2030.

Anthelmintic drugs, essential in treating infections caused by parasitic worms, serve a crucial role in maintaining public health and veterinary sectors. The scope of these drugs encompasses the prevention and treatment of diseases like schistosomiasis, filariasis, and other worm-related conditions affecting both humans and animals. The necessity for these drugs is accentuated by increasing global travel, unregulated use of over-the-counter anthelmintics fostering resistance, and the growing awareness of the importance of animal healthcare. Used predominantly in the agricultural industry and human healthcare facilities, their application ranges from large-scale deworming programs to routine veterinary practices. End-users include hospitals, clinics, pharmaceutical companies, and animal husbandry operations.

KEY MARKET STATISTICS
Base Year [2023] USD 3.30 billion
Estimated Year [2024] USD 3.57 billion
Forecast Year [2030] USD 5.68 billion
CAGR (%) 8.02%

Market growth is influenced by factors such as rising incidences of helminthic infections, advancements in drug formulations enhancing efficacy, and strategic collaborations among key players for market expansion. Recent opportunities lie in emerging markets where deworming is becoming an integral part of public health policies, presenting a lucrative landscape for innovative delivery methods and formulations. Extending the outreach to underserved regions and enhancing awareness could significantly boost market penetration. However, challenges persist, including the growing threat of drug resistance, stringent regulatory policies, and potential side effects constraining the development and adoption of new drugs.

The landscape is ripe for innovation, particularly in developing broad-spectrum anthelmintics with reduced resistance tendencies and drugs tailored to specific regional parasites. Emphasizing research that reduces dosage frequency without compromising effectiveness will also be critical. The nature of the market is characterized by substantial research and regulatory investment, requiring businesses to focus on strategic partnerships and continuous innovation. By investing in enhanced molecular research and bioinformatics, companies can anticipate resistance patterns and tailor solutions to meet emerging needs. The key to market success lies in balancing innovation with stringent compliance and market need anticipation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anthelmintic Drugs Market

The Anthelmintic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing pet adoption coupled with rising focus towards maintaining animal health
    • Increasing spending for animal healthcare and wellness
    • Accelerating prevalence of helminthic infections
  • Market Restraints
    • High cost of antiparasitic drugs
  • Market Opportunities
    • Increasing veterinary healthcare services centers
    • Emergence of anthelmintic drugs as immune modulators in cancer
  • Market Challenges
    • Concerns about the development of drug resistance

Porter's Five Forces: A Strategic Tool for Navigating the Anthelmintic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anthelmintic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anthelmintic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anthelmintic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anthelmintic Drugs Market

A detailed market share analysis in the Anthelmintic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anthelmintic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anthelmintic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anthelmintic Drugs Market

A strategic analysis of the Anthelmintic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anthelmintic Drugs Market, highlighting leading vendors and their innovative profiles. These include Aden Healthcare, Anikem Laboratories, Bayer AG, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Cipla Limited, Dechra Pharmaceuticals PLC, Dr.Reddys Laboratories Inc., Edenbridge Pharmaceuticals LLC, GlaxoSmithKline PLC, Green Cross Remedies, Healthy Life Pharma Private Limited, Johnson & Johnson Services, Inc., Kosher Pharmaceuticals, Lineage Therapeutics Inc, Lupin Limited, Mankind Pharma Ltd., McKesson Corporation, Merck & Co., Inc., Norbrook Laboratories Limited, Novartis AG, Sankur Pharmaceuticals Pvt. Ltd, Takeda Pharmaceutical Company Limited, and Virbac S.A..

Market Segmentation & Coverage

This research report categorizes the Anthelmintic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Benzimidazoles and Piperazine.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Target Pathogen, market is studied across Ancylostoma Duodenale, Ascaris Lumbricoides, Enterobius Vermicularis, and Trichuris Trichiura.
  • Based on Application, market is studied across Animal and Human. The Human is further studied across Gastrointestinal Infections and Parenchymal Neurocysticercosis.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Veterinary Hospitals & Clinics, and Veterinary Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing pet adoption coupled with rising focus towards maintaining animal

health

      • 5.1.1.2. Increasing spending for animal healthcare and wellness
      • 5.1.1.3. Accelerating prevalence of helminthic infections
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of antiparasitic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing veterinary healthcare services centers
      • 5.1.3.2. Emergence of anthelmintic drugs as immune modulators in cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns about the development of drug resistance
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anthelmintic Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Benzimidazoles
  • 6.3. Piperazine

7. Anthelmintic Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Anthelmintic Drugs Market, by Target Pathogen

  • 8.1. Introduction
  • 8.2. Ancylostoma Duodenale
  • 8.3. Ascaris Lumbricoides
  • 8.4. Enterobius Vermicularis
  • 8.5. Trichuris Trichiura

9. Anthelmintic Drugs Market, by Application

  • 9.1. Introduction
  • 9.2. Animal
  • 9.3. Human
    • 9.3.1. Gastrointestinal Infections
    • 9.3.2. Parenchymal Neurocysticercosis

10. Anthelmintic Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies
  • 10.5. Veterinary Hospitals & Clinics
  • 10.6. Veterinary Pharmacies

11. Americas Anthelmintic Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Anthelmintic Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Anthelmintic Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aden Healthcare
  • 2. Anikem Laboratories
  • 3. Bayer AG
  • 4. Boehringer Ingelheim International GmbH
  • 5. Ceva Sante Animale
  • 6. Cipla Limited
  • 7. Dechra Pharmaceuticals PLC
  • 8. Dr.Reddys Laboratories Inc.
  • 9. Edenbridge Pharmaceuticals LLC
  • 10. GlaxoSmithKline PLC
  • 11. Green Cross Remedies
  • 12. Healthy Life Pharma Private Limited
  • 13. Johnson & Johnson Services, Inc.
  • 14. Kosher Pharmaceuticals
  • 15. Lineage Therapeutics Inc
  • 16. Lupin Limited
  • 17. Mankind Pharma Ltd.
  • 18. McKesson Corporation
  • 19. Merck & Co., Inc.
  • 20. Norbrook Laboratories Limited
  • 21. Novartis AG
  • 22. Sankur Pharmaceuticals Pvt. Ltd
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Virbac S.A.

LIST OF FIGURES

  • FIGURE 1. ANTHELMINTIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTHELMINTIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANTHELMINTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANTHELMINTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTHELMINTIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTHELMINTIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PIPERAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANCYLOSTOMA DUODENALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ASCARIS LUMBRICOIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ENTEROBIUS VERMICULARIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TRICHURIS TRICHIURA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENCHYMAL NEUROCYSTICERCOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ANTHELMINTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY TARGET PATHOGEN, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM ANTHELMINTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 280. ANTHELMINTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 281. ANTHELMINTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023